Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Implementing mainstream genetic counseling within the area-wide network of the German Consortium Hereditary Breast and Ovarian Cancer (GC-HBOC): Satisfaction of primary care providers with the provided state-of-the-art training by the Cologne Center.
Herold N, Bredow K, Ernst C, Tüchler A, Blümcke B, Waha A, Keser E, Hauke J, Wappenschmidt B, Hahnen E, Schmutzler RK, Rhiem K. Herold N, et al. J Genet Couns. 2024 Feb;33(1):206-215. doi: 10.1002/jgc4.1870. Epub 2024 Feb 13. J Genet Couns. 2024. PMID: 38351721
SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma.
Abdelrazak Morsy MH, Lilienthal I, Lord M, Merrien M, Wasik AM, Sureda-Gómez M, Amador V, Johansson HJ, Lehtiö J, Garcia-Torre B, Martin-Subero JI, Tsesmetzis N, Tao S, Schinazi RF, Kim B, Sorteberg AL, Wickström M, Sheppard D, Rassidakis GZ, Taylor IA, Christensson B, Campo E, Herold N, Sander B. Abdelrazak Morsy MH, et al. Among authors: herold n. Blood. 2024 May 9;143(19):1953-1964. doi: 10.1182/blood.2023022241. Blood. 2024. PMID: 38237141 Free PMC article.
Clinical implications of incorporating genetic and non-genetic risk factors in CanRisk-based breast cancer risk prediction.
Tüchler A, De Pauw A, Ernst C, Anota A, Lakeman IMM, Dick J, van der Stoep N, van Asperen CJ, Maringa M, Herold N, Blümcke B, Remy R, Westerhoff A, Stommel-Jenner DJ, Frouin E, Richters L, Golmard L, Kütting N, Colas C, Wappenschmidt B, Rhiem K, Devilee P, Stoppa-Lyonnet D, Schmutzler RK, Hahnen E. Tüchler A, et al. Among authors: herold n. Breast. 2024 Feb;73:103615. doi: 10.1016/j.breast.2023.103615. Epub 2023 Nov 29. Breast. 2024. PMID: 38061307 Free PMC article.
A systematic review of recent phase-II trials in refractory or recurrent osteosarcoma: Can we inform future trial design?
van Ewijk R, Cleirec M, Herold N, le Deley MC, van Eijkelenburg N, Boudou-Rouquette P, Risbourg S, Strauss SJ, Palmerini E, Boye K, Kager L, Hecker-Nolting S, Marchais A, Gaspar N; FOSTER Consortium (Fight OsteoSarcoma Through European Research), work package 3 on recurrent/refractory osteosarcoma trials. van Ewijk R, et al. Among authors: herold n. Cancer Treat Rev. 2023 Nov;120:102625. doi: 10.1016/j.ctrv.2023.102625. Epub 2023 Sep 15. Cancer Treat Rev. 2023. PMID: 37738712 Free article. Review.
91 results